Changchun High-tech (000661.SZ) subsidiary GenSci 133 injection's application for domestic production drug registration clinical trial has been accepted.

Zhitong Finance APP reports that Changchun Gaoxin (000661.SZ) has announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as Jinsai Pharmaceutical), has received an Acceptance Notice approved and issued by the National Medical Products Administration. The application for clinical trial registration of the domestically produced GenSci133 injection has been accepted. This drug is a PTH peptide and anti-RANKL antibody fusion protein developed independently by Jinsai Pharmaceutical and belongs to the class of therapeutic biological products. It is intended for the treatment of osteoporosis.